The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial

Holland-Hart, Daniella ORCID: https://orcid.org/0000-0002-1127-5152, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Bridges, Sarah ORCID: https://orcid.org/0000-0002-7665-5770, Nixon, Lisette Sheena ORCID: https://orcid.org/0000-0002-1270-6970, Hawkins, Maria, Crosby, Tom and Nelson, Annmarie ORCID: https://orcid.org/0000-0002-6075-8425 2024. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 14 (9) , e076394. 10.1136/bmjopen-2023-076394

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (442kB)

Abstract

Objectives: This qualitative study explored patients’ experiences and perceptions of the SCOPE2 trial. SCOPE2 examined radiotherapy dose escalation in patients with inoperable oesophageal cancer treated with definitive chemoradiotherapy (dCRT). Setting: Recruitment at five clinical sites in England and Wales, UK. Participants: SCOPE2 trial participants were invited to take part in interviews from across five clinical sites. Participants self-selected to take part in up to three interviews across four different time points: baseline (before treatment) and at 2–3 months, 3–6 months or 6 months+ after baseline. There were five female and five male interview participants. Interventions: Participants were randomised to standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine, or an escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine. Methods: This qualitative study used semistructured longitudinal interviews to explore the impact of treatment on patient outlook and quality of life and the impact of the COVID-19 pandemic. Interview data were thematically analysed. Results: 10 patients participated in 16 longitudinal interviews. Three participants were accompanied by companions. Participants experienced side-effects from radiotherapy and chemotherapy including nausea, throat pain, difficulties eating and regaining appetite, thrombosis and fatigue, although most of these symptoms gradually improved. Participants required more ongoing information and support regarding treatment side-effects and cancer status in order to improve their overall quality of life. Best practice examples involved key contacts providing practical advice and signposting support. Conclusion: Participants of the SCOPE2 trial reported short and longer-term side-effects from chemoradiotherapy, but these usually lessened over time. Participants attempted to be positive about their survival prospects by readjusting their expectations, priorities and lifestyles. Providing patients with ongoing opportunities to discuss detailed and timely information regarding treatment side-effects, aftercare and cancer status could improve the overall health and well-being of patients during oesophageal cancer trials and pathways. Trial registration number: NCT02741856; ISRCTN: 97125464.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc/4.0/, Start Date: 2024-09-23, Type: open-access
Publisher:	BMJ Publishing Group
Date of First Compliant Deposit:	25 September 2024
Date of Acceptance:	21 August 2024
Last Modified:	25 Sep 2024 09:00
URI:	https://orca.cardiff.ac.uk/id/eprint/172364

Actions (repository staff only)

Edit Item